Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 31

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 31
---
 None Extensive experience in life - sciences and healthcare finance, capital raising, and M&A are invaluable to Dynavax as we continue to grow HEPLISAV - B and pursue a diversified vaccine portfolio Deep Track’s Campaign Would Remove Senior Public Biotech and Deal Experience the Board Needs 41 | Elaine Sun Independent Director Since December 2021 x Strong healthcare executive experience: Chief Operating Officer and CFO of Mammoth Biosciences, an in vivo gene editing therapeutics company, and previously SVP and CFO of commercial - stage Halozyme x C - suite vaccine experience: Former CFO and Chief Strategy Officer of SutroVax (now Vaxcyte ), a developer of next - generation pneumococcal conjugate vaccines x Vast experience helping public companies maximize shareholder value: as Investment Banking Managing Director and Head of West Coast Healthcare at Evercore Partners and Managing Director at Merrill Lynch x Proven track record of disciplined and balanced capital allocation: Executed $550M share repurchase followed by new $750M share repurchase plan and $805M convertible notes offering and simultaneous repurchase at Halozyme x Significant transaction experience: >$50B in transaction value across a broad range of pharmaceutical, biotechnology and medical device M&A and financing transactions x Substantial board experience: At both public and private biotechnology companies, including Cirius Therapeutics, BK Medical, and Asher Biotherapeutics Selected Recent Public Company Experience ▪ Independent Director | Recursion Pharmaceuticals (Nasdaq: RXRX) ▪ Former SVP & CFO | Halozyme Therapeutics (Nasdaq: HALO) vs © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 30+ years in finance including strategic planning, and capital raising for biotechnology companies, as well as expertise in navigating complex finance challenges are essential to Dynavax Deep Track’s Campaign Would Remove Deep Industry Financial Expertise Essential for Strategic Oversight 42 | Lauren Silvernail Independent Director Since February 2025 x Extensive senior executive experience over three decades leading commercial, finance and business development functions across the biomedical and pharmaceutical industries x Significant experience in corporate financing and asset sales including as CFO for Revance Therapeutics’ $450M IPO and CFO for ISTA’s $500M sale